Short Therapy and Monotherapy, Plenty of Evidence

A short dual antiplatelet therapy (DAPT) of 1 to 3 months followed by P2Y12 inhibitor monotherapy after second generation drug eluting stent (DES) implantation is safer and as effective as the traditional scheme.

The idea is clear, but why hasn’t aspirin monotherapy been tested as follow up? Is aspirin old fashioned? Are there physiopathological reasons to this choice or is it a matter of cost? These questions are still relevant and require research.

This meta-analysis included 5 randomized studies with over 30,000 patients explores the hypothesis of short DAPT (≤ 3 months) followed by P2Y12 inhibitor vs. 12-month DAPT after 2nd gen DES.

Primary end point were major bleeding and stent thrombosis at one year after randomization.

Major bleeding resulted significantly lower in patients receiving a short scheme (HR 0.63, CI 95% 0.45 to 0.86) followed by P2Y12 monotherapy vs 12-month DAPT.

Improved safety with the short scheme did not pay any cost in terms of stent thrombosis. Thrombosis resulted similar for both schemes (HR 1.19, CI 95% 0.86 to 1.65).


Read also: Diastolic Pressure Could Play a Dirty Trick on Patients Treated for Hypertension.


All secondary end points (all cause death, myocardial infarction or stroke) resulted similar between antiaggregation strategies).

Sensitivity analysis showed consistent results when comparing different randomized studies or patient subgroups. 

Conclusion

One to three month DAPT followed by P2Y12 inhibitor was associated to less major bleeding and similar stent thrombosis rate, death, MI or stroke, compared against the traditional 12 month DAPT scheme.

ehaa739free

Original Title: Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.

Reference: Daniele Giacoppo et al. European Heart Journal (2021) 42, 308–319 doi:10.1093/eurheartj/ehaa739.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2026 | DKCRUSH VIII: IVUS or angiography to guide PCI in complex coronary bifurcations

Intracoronary imaging guidance has become an established recommended strategy in complex coronary lesions. In the specific setting of complex bifurcations, uncertainty remained regarding the...

ACC 2026 | OPTIMAL: IVUS Guidance in PCI of the Unprotected Left Main Coronary Artery

Percutaneous coronary intervention (PCI) is considered an equivalent alternative to coronary artery bypass surgery in patients with left main coronary artery (LMCA) stenosis and...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | DKCRUSH VIII: IVUS or angiography to guide PCI in complex coronary bifurcations

Intracoronary imaging guidance has become an established recommended strategy in complex coronary lesions. In the specific setting of complex bifurcations, uncertainty remained regarding the...

ACC 2026 | OPTIMAL: IVUS Guidance in PCI of the Unprotected Left Main Coronary Artery

Percutaneous coronary intervention (PCI) is considered an equivalent alternative to coronary artery bypass surgery in patients with left main coronary artery (LMCA) stenosis and...

ACC 2026 | Extended follow-up of the TRI-FR study: Edge-to-edge percutaneous repair in isolated severe tricuspid regurgitation

Severe tricuspid regurgitation (TR) is associated with chronic systemic venous congestion, recurrent hospitalizations for heart failure (HF), and a significant deterioration in quality of...